Arax Advisory Partners’s Mereo BioPharma MREO Stock Holding History

Arax Advisory Partners’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.32K	Hold	4,000	–	–	﹤0.01%	3223
2025 Q4	$1.67K	Hold	4,000	–	–	﹤0.01%	3326
2025 Q3	$8.24K	Hold	4,000	–	–	﹤0.01%	2679
2025 Q2	$10.8K	Hold	4,000	–	–	﹤0.01%	1925
2025 Q1	$9K	Hold	4,000	–	–	﹤0.01%	1597
2024 Q4	$14K	Hold	4,000	–	–	﹤0.01%	1361
2024 Q3	$16.4K	Hold	4,000	–	–	﹤0.01%	1164
2024 Q2	$14.4K	Hold	4,000	–	–	﹤0.01%	1098
2024 Q1	$13.2K	Hold	4,000	–	–	﹤0.01%	735
2023 Q4	$9.24K	Hold	4,000	–	–	﹤0.01%	772
2023 Q3	$5.16K	Hold	4,000	–	–	﹤0.01%	870
2023 Q2	$5.28K	Hold	4,000	–	–	﹤0.01%	855
2023 Q1	$2.83K	Hold	4,000	–	–	﹤0.01%	951
2022 Q4	$3K	Hold	4,000	–	–	﹤0.01%	899
2022 Q3	$3K	Hold	4,000	–	–	﹤0.01%	916
2022 Q2	$4K	Hold	4,000	–	–	﹤0.01%	831
2022 Q1	$4K	Hold	4,000	–	–	﹤0.01%	835
2021 Q4	$6K	Hold	4,000	–	–	﹤0.01%	742
2021 Q3	$10K	Buy	+4,000	New	+$10.6K	﹤0.01%	643

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $712M AUM

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

Arax Advisory Partners's MREO Position: Q1 2026 in Review

Arax Advisory Partners held its Mereo BioPharma (MREO) position steady in Q1 2026 at 4,000 shares worth $1.32K. The position accounts for ﹤0.01% of the portfolio, ranked #3223.

Arax Advisory Partners first reported a position in MREO in Q3 2021 and has held it in 19 quarters since. The position peaked at $16.4K in Q3 2024. 63 funds tracked by Wall St. Rank hold MREO as of Q1 2026.

Arax Advisory Partners held 4,000 shares of Mereo BioPharma worth $1.32K as of Q1 2026.
Arax Advisory Partners left its Mereo BioPharma share count unchanged in Q1 2026.
Mereo BioPharma made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3223 holding.
Arax Advisory Partners first reported a position in Mereo BioPharma in Q3 2021 and has held it in 19 quarters since.
Arax Advisory Partners's Mereo BioPharma position peaked at $16.4K in Q3 2024.
63 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.